|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: TMA7 |
Gene summary for TMA7 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | TMA7 | Gene ID | 51372 |
| Gene name | translation machinery associated 7 homolog | |
| Gene Alias | CCDC72 | |
| Cytomap | 3p21.31 | |
| Gene Type | protein-coding | GO ID | GO:0002181 | UniProtAcc | A0A024R306 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51372 | TMA7 | GSM4909280 | Human | Breast | Precancer | 6.63e-05 | -5.29e-01 | 0.0305 |
| 51372 | TMA7 | GSM4909281 | Human | Breast | IDC | 1.55e-67 | 5.63e-01 | 0.21 |
| 51372 | TMA7 | GSM4909286 | Human | Breast | IDC | 1.11e-11 | 2.98e-01 | 0.1081 |
| 51372 | TMA7 | GSM4909287 | Human | Breast | IDC | 8.61e-22 | 2.30e-01 | 0.2057 |
| 51372 | TMA7 | GSM4909288 | Human | Breast | IDC | 5.19e-03 | -2.54e-01 | 0.0988 |
| 51372 | TMA7 | GSM4909290 | Human | Breast | IDC | 1.08e-67 | 6.10e-01 | 0.2096 |
| 51372 | TMA7 | GSM4909292 | Human | Breast | IDC | 9.78e-18 | 5.73e-01 | 0.1236 |
| 51372 | TMA7 | GSM4909293 | Human | Breast | IDC | 9.83e-04 | -8.99e-02 | 0.1581 |
| 51372 | TMA7 | GSM4909294 | Human | Breast | IDC | 1.67e-25 | 1.71e-01 | 0.2022 |
| 51372 | TMA7 | GSM4909296 | Human | Breast | IDC | 2.02e-26 | 2.83e-01 | 0.1524 |
| 51372 | TMA7 | GSM4909297 | Human | Breast | IDC | 1.66e-34 | 8.59e-02 | 0.1517 |
| 51372 | TMA7 | GSM4909298 | Human | Breast | IDC | 5.68e-17 | 3.47e-01 | 0.1551 |
| 51372 | TMA7 | GSM4909301 | Human | Breast | IDC | 1.92e-45 | 4.73e-01 | 0.1577 |
| 51372 | TMA7 | GSM4909302 | Human | Breast | IDC | 4.38e-16 | 1.42e-01 | 0.1545 |
| 51372 | TMA7 | GSM4909304 | Human | Breast | IDC | 3.27e-18 | 3.21e-01 | 0.1636 |
| 51372 | TMA7 | GSM4909306 | Human | Breast | IDC | 6.59e-06 | 2.43e-01 | 0.1564 |
| 51372 | TMA7 | GSM4909309 | Human | Breast | IDC | 3.46e-11 | 8.81e-02 | 0.0483 |
| 51372 | TMA7 | GSM4909311 | Human | Breast | IDC | 1.21e-61 | 1.24e-01 | 0.1534 |
| 51372 | TMA7 | GSM4909312 | Human | Breast | IDC | 2.05e-22 | 1.90e-01 | 0.1552 |
| 51372 | TMA7 | GSM4909313 | Human | Breast | IDC | 9.11e-08 | -1.75e-02 | 0.0391 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Endometrium |  | AEH: Atypical endometrial hyperplasia |
| EEC: Endometrioid Cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00021819 | Breast | Precancer | cytoplasmic translation | 80/1080 | 148/18723 | 1.59e-59 | 8.54e-56 | 80 |
| GO:000218114 | Breast | IDC | cytoplasmic translation | 82/1434 | 148/18723 | 2.60e-52 | 1.48e-48 | 82 |
| GO:000218124 | Breast | DCIS | cytoplasmic translation | 82/1390 | 148/18723 | 2.21e-53 | 1.25e-49 | 82 |
| GO:000218110 | Cervix | CC | cytoplasmic translation | 96/2311 | 148/18723 | 4.87e-51 | 2.91e-47 | 96 |
| GO:000218115 | Cervix | HSIL_HPV | cytoplasmic translation | 86/737 | 148/18723 | 3.97e-82 | 1.91e-78 | 86 |
| GO:000218125 | Cervix | N_HPV | cytoplasmic translation | 42/534 | 148/18723 | 2.61e-30 | 1.19e-26 | 42 |
| GO:0002181 | Colorectum | AD | cytoplasmic translation | 109/3918 | 148/18723 | 3.40e-43 | 2.13e-39 | 109 |
| GO:00021811 | Colorectum | SER | cytoplasmic translation | 102/2897 | 148/18723 | 1.38e-48 | 8.49e-45 | 102 |
| GO:00021812 | Colorectum | MSS | cytoplasmic translation | 108/3467 | 148/18723 | 1.78e-47 | 1.11e-43 | 108 |
| GO:00021813 | Colorectum | MSI-H | cytoplasmic translation | 100/1319 | 148/18723 | 1.50e-79 | 8.31e-76 | 100 |
| GO:000218116 | Endometrium | AEH | cytoplasmic translation | 104/2100 | 148/18723 | 1.01e-64 | 6.07e-61 | 104 |
| GO:000218117 | Endometrium | EEC | cytoplasmic translation | 104/2168 | 148/18723 | 2.53e-63 | 1.52e-59 | 104 |
| GO:000218127 | Esophagus | HGIN | cytoplasmic translation | 108/2587 | 148/18723 | 1.70e-60 | 1.02e-56 | 108 |
| GO:0002181111 | Esophagus | ESCC | cytoplasmic translation | 135/8552 | 148/18723 | 4.17e-32 | 2.65e-29 | 135 |
| GO:00021817 | Liver | NAFLD | cytoplasmic translation | 93/1882 | 148/18723 | 1.44e-55 | 8.41e-52 | 93 |
| GO:000218112 | Liver | Cirrhotic | cytoplasmic translation | 120/4634 | 148/18723 | 2.95e-47 | 1.85e-43 | 120 |
| GO:000218122 | Liver | HCC | cytoplasmic translation | 132/7958 | 148/18723 | 9.09e-33 | 5.76e-30 | 132 |
| GO:000218132 | Liver | Cyst | cytoplasmic translation | 70/496 | 148/18723 | 9.01e-71 | 3.85e-67 | 70 |
| GO:000218120 | Oral cavity | OSCC | cytoplasmic translation | 133/7305 | 148/18723 | 1.94e-38 | 2.46e-35 | 133 |
| GO:0002181110 | Oral cavity | LP | cytoplasmic translation | 124/4623 | 148/18723 | 5.09e-52 | 3.19e-48 | 124 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| TMA7 | SNV | Missense_Mutation | novel | c.83C>A | p.Ala28Asp | p.A28D | Q9Y2S6 | protein_coding | deleterious(0.01) | probably_damaging(0.975) | TCGA-AX-A06F-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | carboplatin | SD |
| TMA7 | SNV | Missense_Mutation | novel | c.89A>C | p.Lys30Thr | p.K30T | Q9Y2S6 | protein_coding | deleterious(0.03) | probably_damaging(0.913) | TCGA-BK-A6W3-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMA7 | SNV | Missense_Mutation | novel | c.88N>G | p.Lys30Glu | p.K30E | Q9Y2S6 | protein_coding | tolerated(0.12) | possibly_damaging(0.874) | TCGA-FI-A2D0-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| TMA7 | deletion | Frame_Shift_Del | novel | c.187delN | p.Lys64SerfsTer19 | p.K64Sfs*19 | Q9Y2S6 | protein_coding | TCGA-BG-A0VW-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| TMA7 | SNV | Missense_Mutation | novel | c.137A>C | p.Lys46Thr | p.K46T | Q9Y2S6 | protein_coding | deleterious(0.04) | benign(0.115) | TCGA-NC-A5HT-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | carboplatin | PR |
| TMA7 | insertion | Frame_Shift_Ins | novel | c.68_69insGCGT | p.Asp23GlufsTer6 | p.D23Efs*6 | Q9Y2S6 | protein_coding | TCGA-56-8504-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |